Concepedia

INTRAVITREAL INJECTION OF 2.5 mg VERSUS 1.25 mg BEVACIZUMAB (AVASTIN) FOR TREATMENT OF CNV ASSOCIATED WITH AMD

Mehdi Modarres, Masood Naseripour, Khalil Ghasemi Falavarjani, Aminollah Nikeghbali, Masih Hashemi, Mohammad Mehdi Parvaresh

Retina · 2009 · 54 citations · 25 references

DOI

Abstract

Intravitreal injection of 2.5 mg bevacizumab has the same efficacy as 1.25 mg, but may be associated with a higher rate of adverse events.

References

25

Ranibizumab for Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, David M. Brown, Jeffrey S. Heier et al. · New England Journal of Medicine · 2006 · 5.8K citations · Full text

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

David M. Brown, Peter K. Kaiser, Mark Michels et al. · New England Journal of Medicine · 2006 · 3.5K citations

Prevalence of Age-Related Macular Degeneration in the United States

Archives of Ophthalmology · 2004 · 2.7K citations · Full text

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders.

Leonard G. Presta, H Chen, Shane J. O'Connor et al. · PubMed · 1997 · 1.6K citations

, , +15

Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration

Robert L. Avery, Dante J. Pieramici, Melvin Rabena et al. · Ophthalmology · 2006 · 1.1K citations

, , +2